Clinical Trials Logo

Lymphoma, T-Cell clinical trials

View clinical trials related to Lymphoma, T-Cell.

Filter by:

NCT ID: NCT03701022 Not yet recruiting - NK/T-cell Lymphoma Clinical Trials

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Start date: October 20, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 combined with Apatinib in subjects with relapsed or refractory NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.

NCT ID: NCT03598959 Not yet recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma

Tofacitinib Combined With Chidamide in R/R ENKTCL

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.

NCT ID: NCT03553537 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphoma

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Start date: June 2018
Phase: Phase 3
Study type: Interventional

Primary objective of the study is to compare the efficacy and safety of decitabine plus CHOP (D-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL).

NCT ID: NCT03054532 Not yet recruiting - LYMPHOMA Clinical Trials

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

Start date: July 2017
Phase: Phase 2
Study type: Interventional

This is a multi-center, open-label, phase II study of durvalumab in combination with lenalidomide for treatment of relapsed/refractory NK/T-cell lymphoma (NKTCL). The study will employ a 2-stage Simon Optimal design with 80% power and type 1 error rate (significance level) of 5%. Stage 1 will involve 8 patients and will require at least 2 patients to achieve the primary end point of overall response in order to proceed onto to stage 2, which will have a target enrolment of 14 patients.

NCT ID: NCT03051581 Not yet recruiting - Clinical trials for Lymphoma, T-Cell, Peripheral

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of PTCL can predict disease progression

NCT ID: NCT03051568 Not yet recruiting - Clinical trials for Lymphoma, T-Cell, Peripheral

Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F-FDG PET/CT and predict disease progression during chemotherapy or survival in PTCL.

NCT ID: NCT03051555 Not yet recruiting - Clinical trials for Lymphoma, Extranodal NK-T-Cell

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma can predict disease progression

NCT ID: NCT03051542 Not yet recruiting - Clinical trials for Lymphoma, Extranodal NK-T-Cell

Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F- FDG PET/CT and predict disease progression during chemotherapy or survival in NK/T-cell lymphoma.

NCT ID: NCT03023358 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Start date: February 2017
Phase: Phase 3
Study type: Interventional

The prognosis for Peripheral T cell lymphomas (PTCL) remains poor in comparison to B cell NHL. This is largely due to lower response rates and less durable responses to standard combination chemotherapy regimens such as CHOP. Whether CDOP plus Chidamide can improve the prognosis for PTCL.

NCT ID: NCT03000738 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas

Start date: December 2016
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.